Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Li, Qigui ^a   O'Neil, Michael ^a   Xie, Lisa ^a   Caridha, Diana ^a   Zeng, Qiang ^a   Zhang, Jing ^a   Pybus, Brandon ^a   Hickman, Mark ^a   Melendez, Victor ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

In vivo image system; Liver stage; Malaria infections; Pharmacokinetic profile; Primaquine; Prophylactic activity; Tafenoquine

Indexed keywords

PRIMAQUINE; TAFENOQUINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOLUMINESCENCE; C57BL 6 MOUSE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG TISSUE LEVEL; IN VIVO STUDY; INFECTION PREVENTION; MALARIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; PARASITEMIA; SINGLE DRUG DOSE; SOLDIER; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMINOQUINOLINES; ANIMALS; ANTIMALARIALS; AREA UNDER CURVE; FLOW CYTOMETRY; HALF-LIFE; LIVER; MALARIA; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; PLASMODIUM BERGHEI; PRIMAQUINE; SPOROZOITES;

EID: 84899479595     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-141     Document Type: Article

References (33)

1. WHO, Guidelines for the Treatment of Malaria Geneva, Switzerland: World Health Organization 2006 Available at: http://www.who.int/malaria/publications/ atoz/9789241547925/en/. Accessed April 2014
2. Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives. Shiraki H, Kozar MP, Melendez V, Hudson TH, Ohrt C, Magill AJ, Lin AJ, J Med Chem 2011 54 131 142 10.1021/jm100911f 21141892
3. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Brueckner RP, Coster T, Wesche DL, Shmuklarsky M, Schuster BG, Antimicrob Agents Chemother 1998 42 1293 1294 9593172
4. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S, Clin Infect Dis 2004 39 1095 1103 10.1086/424508 15486831
5. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL, Clin Infect Dis 2003 36 541 549 10.1086/367542 12594633
6. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Shanks GD, Oloo AJ, Aleman GM, Ohrtt C, Klotz FW, Braitman D, Horton J, Brueckner R, Clin Infect Dis 2001 33 1968 1974 10.1086/324081 11700577
7. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria. Walsh DS, Eamsila C, Sasiprapha T, Sangkharomya S, Khaewsathien P, Supakalin P, Tang DB, Jarasrumgsichol P, Cherdchu C, Edstein MD, Rieckmann KH, Brewer TG, J Infect Dis 2004 190 1456 1463 10.1086/424468 15378438
8. Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. Walsh DS, Looareesuwan S, Wilairatana P, Heppner DG Jr, Tang DB, Brewer TG, Chokejindachai W, Viriyavejakul P, Kyle DE, Milhous WK, Schuster BG, Horton J, Braitman DJ, Brueckner RP, J Infect Dis 1999 180 1282 1287 10.1086/315034 10479159
9. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, Leggat PA, Pickford P, Kerr C, Ohrt C, Prescott W, Tafenoquine Study Team, Antimicrob Agents Chemother 2010 54 792 798 10.1128/AAC.00354-09 19995933
10. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel. Nasveld P, Kitchener S, Edstein M, Rieckmann K, Trans R Soc Trop Med Hyg 2002 96 683 684 10.1016/S0035-9203(02)90351-2 12625150
11. The efficacy of WR238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivax. Cooper RD, Milhous WK, Rieckmann KH, Trans R Soc Trop Med Hyg 1994 88 691 692 10.1016/0035-9203(94)90232-1 7886774
12. Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats. Queener SF, Dean RA, Bartlett MS, Milhous WK, Berman JD, Ellis WY, Smith JW, J Infect Dis 1992 165 764 768 10.1093/infdis/165.4.764 1532406
13. 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Bartlett MS, Queener SF, Tidwell RR, Milhous WK, Berman JD, Ellis WY, Smith JW, Antimicrob Agents Chemother 1991 35 277 782 10.1128/AAC.35.2.277 2024961
14. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Peters W, Robinson BL, Milhous WK, Ann Trop Med Parasitol 1993 87 547 552 8122915
15. In vitro activity of tafenoquine alone and in combination with artemisinin against Plasmodium falciparum. Ramharter M, Noedl H, Thimasarn K, Wiedermann G, Wernsdorfer G, Wernsdorfer WH, Am J Trop Med Hyg 2002 67 39 43 12363062
16. Tafenoquine: a promising new antimalarial agent. Crockett M, Kain KC, Expert Opin Investig Drugs 2007 16 705 715 10.1517/13543784.16.5.705 17461742
17. Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR Mice and Anopheles stephensi mosquitoes. Coleman RE, Clavin AM, Milhous WK, Am J Trop Med Hyg 1992 46 169 182 1539752
18. Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. Ploemen IH, Prudêncio M, Douradinha BG, Ramesar J, Fonager J, van Gemert GJ, Luty AJ, Hermsen CC, Sauerwein RW, Baptista FG, Mota MM, Waters AP, Que I, Lowik CW, Khan SM, Janse CJ, Franke-Fayard BM, PLoS One 2009 4 7881 10.1371/journal.pone.0007881 19924309
19. Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. Ponsa N, Sattabongkot J, Kittayapong P, Eikarat N, Coleman RE, Am J Trop Med Hyg 2003 69 542 547 14695093
20. In vivo imaging of malaria parasites in the murine liver. Thiberge S, Blazquez S, Baldacci P, Renaud O, Shorte S, Ménard R, Amino R, Nat Protoc 2007 2 1811 1818 10.1038/nprot.2007.257 17641649
21. Evaluation of immunity against malaria using luciferase-expressing Plasmodium berghei parasites. Ploemen I, Behet M, Nganou-Makamdop K, van Gemert GJ, Bijker E, Hermsen C, Sauerwein R, Malar J 2011 10 350 10.1186/1475-2875-10- 350 22152047
22. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, et al. Science 2011 334 1372 1377 10.1126/science.1211936 22096101
23. Reduced Plasmodium berghei sporozoite liver load associates with low protective efficacy after intradermal immunization. Nganou-Makamdop K, Ploemen I, Behet M, Van Gemert GJ, Hermsen C, Roestenberg M, Sauerwein RW, Parasite Immunol 2012 34 562 569 10.1111/pim.12000.x 23171040
24. Quantitative analysis of Plasmodium berghei liver stages by bioluminescence imaging. Annoura T, Chevalley S, Janse CJ, Franke-Fayard B, Khan SM, Methods Mol Biol 2013 923 429 443 22990796
25. 4(1H)-Quinolones with liver stage activity against Plasmodium berghei. Lacrue AN, Sáenz FE, Cross RM, Udenze KO, Monastyrskyi A, Stein S, Mutka TS, Manetsch R, Kyle DE, Antimicrob Agents Chemother 2013 57 417 424 10.1128/AAC.00793-12 23129047
26. Noninvasive real-time monitoring of liver-stage development of bioluminescent Plasmodium parasites. Mwakingwe A, Ting LM, Hochman S, Chen J, Sinnis P, Kim K, J Infect Dis 2009 200 1470 1478 10.1086/606115 19811100
27. Plasmodium liver load following parenteral sporozoite administration in rodents. Ploemen IH, Chakravarty S, van Gemert GJ, Annoura T, Khan SM, Janse CJ, Hermsen CC, Hoffman SL, Sauerwein RW, Vaccine 2013 31 3410 3416 10.1016/j.vaccine.2012.09.080 23063834
28. Quantitative bioluminescent imaging of pre-erythrocytic malaria parasite infection using luciferase-expressing Plasmodium yoelii. Miller JL, Murray S, Vaughan AM, Harupa A, Sack B, Baldwin M, Crispe IN, Kappe SH, PLoS One 2013 8 60820 10.1371/journal.pone.0060820 23593316
29. Simple centrifugation method for rapid separation of sporozoites from mosquitoes. Ozaki LS, Gwadz RW, Godson GN, J Parasitol 1984 70 831 833 10.2307/3281779 6150971
30. Development and validation of flow cytometric measurement for parasitaemia using autofluorescence and YOYO-1 in rodent malaria. Xie L, Li Q, Johnson J, Zhang J, Milhous W, Kyle D, Parasitology 2007 134 1151 1162 10.1017/S0031182007002661 17445324
31. Development and validation of flow cytometric measurement for parasitemia in cultures of P. falciparum vitally stained with YOYO-1. Li Q, Gerena L, Xie L, Zhang J, Kyle D, Milhous W, Cytometry A 2007 71A 297 307 10.1002/cyto.a.20380
32. In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei. Bates MB, Meshnick SR, Sigler CI, Leland P, Hollingdale MR, Am J Trop Med Hyg 1990 42 532 537 2164790
33. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Brueckner RP, Lasseter KC, Lin ET, Schuster BG, Am J Trop Med Hyg 1998 58 645 649 9598455